(Adds background)
Dec 9 (Reuters) - An advisory committee to the U.S. Food andDrug Administration recommended on Wednesday that the agencyapprove Teva Pharmaceutical Industries Ltd's The panel voted unanimously that the drug should not beapproved for children aged 12 to 17. The FDA is not required to follow the advice of its expertadvisory panels, but typically does so. Reslizumab is an antibody drug designed to be givenintravenously once every four weeks. The FDA, according to a Teva spokeswoman, is slated todecide by March whether to approve the drug, which would be soldunder the brand name Cinqair. The agency last month approved a similar asthma drug,Nucala, or mepolizumab, which is produced by GlaxoSmithKline Plc, for patients age 12 and older. Asthma is a chronic disease that causes inflammation in theairways of the lungs. According to the Centers for DiseaseControl and Prevention, as of 2013, more than 22 million peoplein the United States had asthma, and there are more than 400,000asthma-related hospitalizations each year. (Reporting By Deena Beasley; Editing by Meredith Mazzilli andLeslie Adler)